Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors at 10 institutions in 1 country.
Annabelle R CharbitCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.ORCID 0000-0002-5799-0581
Maude A LiegeoisCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.ORCID 0000-0001-7015-5970
Wilfred W RaymondCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.
Suzy A A ComhairInflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Mats W JohanssonPulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States.ORCID 0000-0001-5699-978X
Annette T HastiePulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University, Winston-Salem, North Carolina, United States.ORCID 0000-0001-6607-7797
Eugene R BleeckerAsthma and Airway Disease Research Center, University of Arizona, Phoenix, Arizona, United States.
Merritt FajtPulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Mario CastroPulmonary, Critical Care and Sleep Medicine, University of Kansas, Kansas City, Kansas, United States.ORCID 0000-0001-6328-8994
Kaharu SuminoDivision of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, Missouri, United States.
Serpil C ErzurumInflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.ORCID 0000-0001-5202-9065
Elliot IsraelDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.ORCID 0000-0002-2470-856X
Nizar N JarjourPulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States.
David T MaugerDivision of Biostatistics and Bioinformatics, Penn State University, Hershey, Pennsylvania, United States.ORCID 0000-0002-4663-5285
Wendy C MoorePulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University, Winston-Salem, North Carolina, United States.
Sally E WenzelPulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0002-4242-0164
Prescott G WoodruffCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.
Bruce D LevyDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.ORCID 0000-0001-9515-5731
Monica C TangCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.ORCID 0000-0001-8847-5817
John V FahyCardiovascular Research Institute (CVRI), University of California, San Francisco, California, United States.ORCID 0000-0001-5427-9308
University of California, San Francisco · USBrigham and Women's Hospital · USCleveland Clinic · USUniversity of Pittsburgh · USUniversity of Wisconsin–Madison · USWake Forest University · USPennsylvania State University · USUniversity of Arizona · USUniversity of Kansas · USWashington University in St. Louis · US
Funding
Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle · 2008 to 2026
$41.1M
Role of miRNAs in Th2-Driven inflammation in AsthmaP01HL107202 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 2012 to 2023
$23.3M
Protein carbohydrate interactions in the pathophysiology of asthma exacerbationsR01HL080414 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI John V Fahy · 2005 to 2026
$9.2M
Clinical Coordinating Center for the Severe Asthma Research Program (SARP)U10HL109086 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAUGER, DAVID T. · 2011 to 2017
$8.1M
AMSA: ALXR/FBR Mediated Signaling in Severe AsthmaU10HL109172 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, LEVY, BRUCE D · 2011 to 2016
$4.2M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Clinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0M
Implications and Stability of Clinical and Molecular Phenotypes of Severe AsthmaU10HL109152 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WENZEL, SALLY E · 2011 to 2016
$3.9M
Stability of Severe Asthma Phenotypes: Impact of ExacerbationsU10HL109168 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI JARJOUR, NIZAR N · 2011 to 2016
$3.9M
Severe Asthma Research Program (SARP)-Washington UniversityU10HL109257 · NHLBI · WASHINGTON UNIVERSITY · PI CASTRO, MARIO · 2011 to 2016
$3.8M
Longitudinal Phenomics and Genetics of Severe AsthmaU10HL109164 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND, MEYERS, DEBORAH A. · 2011 to 2016
$3.8M
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and PhysiologyR01HL164787 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2022 to 2025
Secreted deoxyribonucleases (DNases), such as DNase-I and DNase-IL3, degrade extracellular DNA, and endogenous DNases have roles in resolving airway inflammation and guarding against autoimmune responses to nucleotides. Subsets of patients with asthma have high airway DNA levels, but information about DNase activity in health and in asthma is lacking. To characterize DNase activity in health and in asthma, we developed a novel kinetic assay using a Taqman probe sequence that is quickly cleaved by DNase-I to produce a large product signal. We used this kinetic assay to measure DNase activity in sputum from participants in the Severe Asthma Research Program (SARP)-3 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A novel DNase assay reveals low DNase activity in severe asthma. · full record | OpenQuestion